Polianta Ltd’s Regeneron Pharmaceuticals REGN Stock Holding History

Polianta Ltd’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,600	Closed	-$1.36M	–	97
2025 Q2	$1.36M	Buy	+2,600	New	+$1.45M	0.59%	33

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Polianta Ltd's REGN Position: Q3 2025 in Review

Polianta Ltd sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 2,600 shares — an estimated $1.36M sold.

Polianta Ltd first reported a position in REGN in Q2 2025 and held it in 1 quarter. The position peaked at $1.36M in Q2 2025. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Polianta Ltd reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Polianta Ltd sold 2,600 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $1.36M.
Polianta Ltd first reported a position in Regeneron Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Polianta Ltd's Regeneron Pharmaceuticals position peaked at $1.36M in Q2 2025.
1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Polianta Ltd's 13F filing for Q3 2025, filed 16 Oct 2025.